As Turing & Valeant Cast A Negative Shadow, Larry Robbins Fumes – ValueWalk Premium

As Turing & Valeant Cast A Negative Shadow, Larry Robbins Fumes

While the healthcare sector has experienced a setback recently, having “become short-term auto-correlated to the downside,” Hedge Fund titan Larry Robbins of Glenview Capital frets about the recent problems that have befallen the healthcare sector, which has been especially hard hit during the recent market downturn. Using uncommonly strong language in an investor letter, he appeared to cast a dubious eye towards quick to profit pharmaceutical firms who have raised prices so egregiously that it caused a harsh political focus to taint an entire industry. In an investor letter reviewed by ValueWalk, he also cast a wary eye on the accounting and business practices of a "high-profile consolidator" in the pharmaceutical sector.

Nonetheless Robbins thinks his investment theses regarding the overall healthcare sector is positive and his correlation strategy of using different sub-categories within the industry remains valid going forward.

Larry Robbins appears to target Martin Shkreli as healthcare stocks plummet amid political controversy.

As previously reported in ValueWalk, Larry Robbins has experienced a “disappointing” results over the past three months. While most stocks suffered from late August to September, one sector has particularly been hard hit. The healthcare equity exposure maintained inside the Glenview portfolio suffered punitive losses as many of the stock sub categories correlated to one during the stock market turbulence experienced earlier this year.


This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email or click Chat.

Saved Articles

The Life and Career of Charlie Munger

Charlie is more than just Warren Buffett’s friend and Berkshire Hathaway’s Vice Chairman – Buffett has actually credited him with redefining how he looks at investing. Now you can learn from Charlie firsthand via this incredible ebook and over a dozen other famous investor studies by signing up below:

  • Learn from the best and forever change your investing perspective
  • One incredible tidbit of knowledge after another in the page-turning masterpiece of a book
  • Discover the secrets to Charlie’s success and how to apply it to your investing
Never Miss A Story!
Subscribe to ValueWalk Newsletter. We respect your privacy.

Here’s a Tip: Read What Professional Investors Read

ValueWalk Premium is for investors looking to improve their investment process AND keep up-to-date on the latest industry trends.

It’s THE resource for value investing and hedge funds. 📈

And with a free three-day trial and $29.99 per month thereafter, it’s a value in its own right.

Sign up now. 👇